Congratulations to Acuitas’ Chief Legal Officer & Vice President, Business Development, Miranda Lam, KC, on being appointed as the new Chair of the UBC Board of Governors, effective August 1, 2024. Acuitas is made up of many proud #UBCalumni, and we are honoured to count the new Board Chair amongst our team members. Miranda has a long history of contributing to her community, including through board service. In 2023, she was recognized as a YWCA Metro Vancouver Woman of Distinction (2023) in the Business & the Professions category for her efforts. https://lnkd.in/g_eX4ZiY You can learn more about Miranda’s appointment here: https://lnkd.in/gbDp9Fic. #AcuitasTherapeutics #Leadership #UBCBoardChair #CommunityImpact #Vancouver #YVR
Acuitas Therapeutics, Inc.
Biotechnology
Vancouver, British Columbia 10,651 followers
Enabling new medicines through nanotechnology research and development.
About us
Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To provide our partners with the best LNP delivery technology for nucleic acid therapeutics · To support our partners to rapidly advance new therapeutics to address unmet medical needs · To continually innovate to maintain and strengthen our LNP technological lead Acuitas partners locally and globally with companies, academic institutes and other organizations to improve human health.
- Website
-
http://acuitastx.com
External link for Acuitas Therapeutics, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Privately Held
- Founded
- 2009
Locations
-
Primary
6190 Agronomy Rd
Vancouver, British Columbia V6T, CA
Employees at Acuitas Therapeutics, Inc.
Updates
-
The Acuitas Business Development (BD) Team is dedicated to building transformative partnerships to realize nucleic acid therapeutics to improve human health. The BD Team is the first point of contact for a potential partner. This engaged team works around time zones, geographic borders and languages – helping to set up a solid foundation for our partners’ success. Please reach out if you are interested in exploring a partnership with Acuitas. https://lnkd.in/gdqBDce4 #AcuitasTherapeutics #LipidNanoparticles #LNP #mRNA #NucleicAcids #Biotechnology #GeneTherapy #Nanotechnology
-
We celebrate the diverse identities within the 2SLGBTQIA+ community. Canada Pride 2024 serves as a call to action, highlighting the importance of advocating for 2SLGBTQIA+ rights on a global scale. Starting today, until August 4, Vancouver will be transformed into a hub of celebration featuring VanPrideFest and the Vancouver Pride Parade. This year, Vancouver’s inaugural Human Rights Conference has been added, which will address the urgent challenges confronting the Queer community, here in Canada and globally. For more information on Canada Pride 2024, please visit: https://lnkd.in/gpkchHda. #AcuitasTherapeutics #Pride #CanadaPride2024 #Vancouver #YVR
-
PUBLICATION ALERT Collaboration with scientists from the Gouon-Evans Lab at the Center for Regenerative Medicine and the Weissman and Pardi Labs at University of Pennsylvania Perelman School of Medicine studying the stimulation of key regenerative pathways in transplanted PHHs using human HGF and human EGF delivered with mRNA-LNP drastically improves donor PHH engraftment as an alternative to liver transplantation and restores liver function (Nature Communications 2024). https://lnkd.in/eVrq3AgV #AcuitasTherapeutics #LipidNanoparticles #LNP #mRNA #NucleicAcids #LiverDisease
-
As a Major Partner, we strongly support Science World’s goal to inspire the next generation of problem solvers, world changers and nerds. In fact, we feel seen by this description – Acuitas is proudly made up of these very same types of people. We know how important the next generation of problem solvers and world changers are to the future of the world. We can’t say enough good things about our partner. https://lnkd.in/gACf8F2 #AcuitasTherapeutics #Science #STEAM #STEM #Vancouver #YVR
-
On Wednesday, a group of Acuitas colleagues played basketball on the court outside of our workspace during lunch. Even though some had never played before, everyone had a lot of fun and laughs. #AcuitasTherapeutics #AGreatPlaceToWork #ILoveMyJob #Vancouver #YVR #LNP #LipidNanoparticles
-
Working with our partners, we provide deep expertise in the entire drug development process and, enabled by our best-in-class lipid nanoparticle delivery technology, we help to accelerate their path to the clinic and the market. We offer a true partnership where collaboration is the foundation and success is shared. You can read articles published by scientific journals on studies that we have participated in with partners here: https://lnkd.in/g57xwsc. #AcuitasTherapeutics #mRNA #LipidNanoparticles #LNP #NucleicAcidTherapeutics
-
Acuitas was away from the office on Friday for a day of team-building exercises on the ocean – kayaking, games and a fabulous lunch. What a great way to start the weekend, connect with our colleagues, and have fun in a beautiful place. #AcuitasTherapeutics #AGreatPlaceToWork #ILoveMyJob #Vancouver #YVR #LNP #LipidNanoparticles
-
The entire Acuitas team is responsible for our great company culture. It’s just one of the many reasons why we were named one of Canada’s Top Small & Medium Employers and one of BC’s Top Employers in 2024. Are you interested in working at Acuitas? You can learn about our exceptional corporate culture here: https://lnkd.in/gwPkbkC5. #AcuitasTherapeutics #mRNA #LipidNanoparticles #LNP #NucleicAcidTherapeutics #Vancouver #YVR #AGreatPlaceToWork
-
Congratulations to Dr. Pieter Cullis and Phil Felgner on their recent article published by Nature Reviews Drug Discovery on the 60-year evolution of lipid nanoparticles for nucleic acid delivery. Dr. Cullis is one of three co-founder Acuitas Therapeutics with Dr. Tom Madden and Dr. Michael Hope. https://lnkd.in/d-Pr2wai #AcuitasTherapeutics #LipidNanoparticles #LNP #mRNA #COVID
The 60-year evolution of lipid nanoparticles for nucleic acid delivery - Nature Reviews Drug Discovery
nature.com